Pernix therapeutics holdings, inc. (PTX)
CashFlow / Quarterly
Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Net loss

-

-13,513

-18,584

-

-

-21,616

-29,462

-86,077

-26,438

-31,139

-25,936

-81,666

-10,740

-32,235

-23,674

-7,819

-11,691

-6,234

-9,542

-6,224

-5,823

-5,676

-7,910

-1,399

-270

-931

1,191

3,876

1,994

1,501

975

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

147

81

88

93

92

94

91

116

104

370

114

110

104

78

69

69

53

59

150

183

182

163

143

161

111

25

26

29

25

20

21

Amortization of intangibles

2,275

1,376

9,806

-

18,151

18,152

18,485

-

20,625

20,711

23,550

-

25,629

22,248

18,364

-

10,106

1,910

2,041

-

2,136

2,113

1,681

720

774

771

612

582

578

573

471

Amortization of deferred financing costs

929

960

950

920

894

862

620

616

610

609

605

769

568

600

793

942

614

464

313

175

172

833

114

-

-

-

-

-

-

-

-

Accretion expense

1,338

1,263

1,205

1,442

1,135

1,354

1,348

1,402

903

881

871

850

820

616

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

PIK Interest

437

506

466

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest accretion of notes receivable

-

-

-

-

-

-

-

-

-

-

-

0

-32

-47

-48

-49

-72

-85

-86

-86

-28

0

0

-

-

-

-

-

-

-

-

Deferred income benefit

-

-

-

-

-

-

-

-224

0

161

-137

16,905

-2,735

-4,193

-3,231

-6,409

655

422

-6,421

-12,286

-7,420

-1,873

-936

-1,318

-384

-133

0

141

-766

-670

-978

Deferred income tax (benefit) provision

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

425

-

-

-

-

Loss on disposal of fixed assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-6

0

-15

-4

-

-

0

0

Stock compensation expense

443

485

400

556

531

659

745

638

-159

770

1,469

1,516

1,343

1,214

1,871

1,289

878

740

1,779

533

491

479

545

752

678

727

496

410

357

303

211

Fair market value change in contingent consideration

0

-120

263

-1,389

884

-886

346

-2,694

516

-3,972

-5,502

3,458

-3,596

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Expense for stock options issued in exchange for services

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

119

122

131

148

146

144

163

188

188

175

137

0

0

Fair market value change in derivative liability

-18

-40

19

-85

-46

-270

354

-2,191

209

-159

-6,794

-85

-10,527

-8,703

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of put right

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,145

1,830

2,140

-

0

0

0

-

-

-

-

Change in fair value of contingent consideration and put right

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-522

0

-283

0

0

0

0

-

-

-

-

Loss on sale of PML (including impairment)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-13

215

6,457

-

-

-

-

-

-

-

-

-

-

-

-

(Increase) decrease in operating assets, net of effects of acquisitions:
Loss from the operations of the joint venture

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0

0

0

240

122

100

261

330

Impairment charge

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

Accounts receivable

3,555

-1,731

-8,311

-3,051

3,122

14,246

-19,729

5,957

-3,675

-3,838

-9,453

621

14,193

1,554

714

-7,717

29,121

-9,127

6,203

2,344

-3,342

-3,871

-7,293

4,741

4,120

-777

-4,199

-3,050

12,572

-236

-3,441

Income tax receivable

-56

33

-55

-306

-23

-228

-734

-1,937

-3,679

174

121

-2,049

5,737

-807

1,264

2,507

55

4,219

-189

-

-

-

-

-

-

-

-

-

-

-

92

Income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5,052

-111

-3,434

964

-876

-30

-1,393

-

-

-

-

Inventory

-3,218

-349

11

-2,734

-352

1,038

-331

-507

-1,411

-2,134

1,792

-626

1,596

-2,793

1,379

-230

-954

1,140

-1,836

-2,503

-766

701

-4,837

840

-597

1,627

-1,220

-1,257

3,733

-311

-48

Prepaid expenses and other assets

6,137

-1,195

-1,337

-10,435

7,456

-1,571

720

1,168

1,243

-692

-1,186

531

-4,646

2,289

-645

-403

2,583

381

-417

-789

2,053

355

560

32

162

457

-471

442

-177

-287

297

Increase (decrease) in operating liabilities, net of effects of acquisitions:
Accounts payable and accrued expenses

1,446

165

-1,904

864

-3,871

2,656

-1,764

-955

-2,668

-11,790

7,453

-8,337

15,057

3,609

-3,647

-4,068

17,211

-2,756

1,774

-3,498

-5,703

6,618

-815

-1,926

-670

1,491

-738

-1,779

2,988

988

-1,457

Accrued allowances

4,730

-6,235

3,946

-1,945

2,515

-71

-5,151

4,606

609

-6,737

-195

4,720

5,760

461

-867

18,318

0

-4,718

4,718

-

-

-

-

-

-

-

-

-

-

-

-

Accrued allowances

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,760

-6,784

-449

4,046

-1,610

1,223

-2,115

1,696

3,604

322

2,337

Interest payable

-3,522

4,439

-4,897

4,508

-4,431

3,973

-4,568

4,279

-4,555

4,447

-5,177

5,248

-5,545

7,935

-5,347

10,012

0

-478

478

-

-

-

-

-

-

-

-

-

-

-

-

Other liabilities

-671

28

-1,717

-350

-161

201

-1,918

-348

-34

120

-2,366

-2,422

-217

-1,719

-615

-4,672

0

4,137

-4,137

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-17,319

-7,809

-267

3,279

-41

-8,377

-800

6,389

-2,104

-17,467

-3,319

-3,854

-972

9,121

-19,044

32,149

-13,057

-4,078

-6,118

2,896

-8,894

-3,043

2,510

-2,599

-5,769

1,613

4,829

8,134

-7,252

3,503

5,012

Cash flows from investing activities:
Acquisitions

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

Acquisitions of licenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-2,400

-

-

-

-

Acquisition of Cypress

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-309

-

-

-

-

-

-

-

-

Purchase of software and equipment

41

94

4

13

2

0

3

20

15

722

227

183

303

503

223

616

142

304

115

18

231

143

135

-

-

-

-

-

-

-

75

Purchase of equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-20

-

-

-

-

Net cash used in investing activities

-69,266

352

-4

1,987

-2

0

-3

-20

-15

-1,305

-227

-1,992

-703

-81,430

-223

-2,526

-248,195

914

-115

-14

19,360

4,484

-445

-51,707

-5,277

-5,490

-2,420

-1,042

-1,133

18

-18

Cash flows from financing activities:
Net proceeds from revolving credit facility

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

0

0

0

1,000

Proceeds from issuance of Convertible Notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

65,000

-

-

-

0

-

-

-

-

-

-

-

-

Cash acquired in connection with acquisition of Somaxon

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

2,880

-

-

-

-

-

-

-

-

Payments on contracts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

166

633

900

550

2,330

330

330

-700

330

300

1,300

Payments on Treximet Secured Notes

0

0

5,373

0

4,699

0

12,812

0

5,498

0

14,908

-

10,013

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment on financing costs

0

0

221

1

13,586

0

0

-

-

-

-

-

-

-

-

85

7,833

30

6,201

-

-

-

60

-

-

-

-

-

-

-

-

Net payments on credit facilities

-

-

-

-

-

-

-

0

0

0

-1,000

5,000

2,059

-2,717

3,313

-11,438

5,654

8,081

-11,812

-

-

-

-

-

-

-

-

-

-

-

-

Payments on mortgages and capital leases

14

11

13

-3

13

19

23

27

19

15

16

16

15

6

7

0

0

12

34

24

38

37

43

-

-

-

-

-

-

-

-

Tax benefit on stock-based awards

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-551

0

16

131

63

0

0

84

-

-

-

-

-

-

-

-

Tax benefit on stock-based awards

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

167

-23

38

133

14

43

80

0

Shares withheld for the payment of taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-356

0

-74

-679

-22

0

-111

-96

0

0

-37

37

-

-

-

-

Proceeds from issuance of stock in additional offering, net of issuance costs of $846 for the year ended December 31, 2012

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0

0

21,350

2,400

0

19,259

0

0

Payments on mortgages and capital leases

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-40

-80

0

0

-

-

-

-

Principal payments received on notes receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

56

56

Proceeds from issuance of common stock, net of tax and costs

-

-

-

-

-

-

-

-

-

-

-

-

0

132

144

-

-

-

294

-

-

-

0

-

-

-

-

182

46

60

0

Shares withheld for the payment of taxes

-

-

-

-

-

-

-

-1

0

5

19

-

0

3

109

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payments on term loan

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7,700

1,774

525

-

-

-

-

-

-

-

-

Stock issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

91,069

440

-5,607

313

12,943

-19

-12,835

1,485

1,433

11,333

-15,943

4,794

-7,969

120,211

3,341

-11,197

216,890

8,104

46,437

3,074

-9,823

-18,652

1,171

40,293

-2,423

15,184

2,240

-103

19,313

159

-300

Net decrease in cash and cash equivalents

4,586

-7,017

-5,878

5,579

12,900

-8,396

-13,638

7,854

-686

-7,439

-19,489

-1,052

-9,644

47,902

-15,926

18,426

-44,362

4,940

40,204

5,956

642

-17,211

3,237

-14,013

-13,471

11,307

4,650

6,988

10,927

3,681

4,693

Cash paid for income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

497

-

49

-0

1,321

35

867

281

1,297

3,264

1,752

2,100

1,793

Acquisition of product licenses - contract payable balance

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Accrued 2011 bonus paid in unrestricted common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

199

-

0

0

0

Interest paid during the period

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

448

-

-1,162

1,240

761

83

9

53

53

27

52

61

36

Acquisition of license - contract payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,500

-

0

0

500

-1,370

0

0

2,000

-

-

-

-

Acquisition of license and supply agreement - contract payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

850

0

0

-

-

-

-

Acquisition of Cypress and Somaxon - Purchase price adjustment (see Note 4)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,250

0

0

0

0

-

-

-

-

Acquisition of Somaxon - Fair value of common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0

0

23,840

0

0

0

0

-

-

-

-